Pharvaris (PHVS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharvaris, a biopharmaceutical company focusing on oral treatments for hereditary angioedema (HAE), has scheduled its annual shareholder meeting for June 28, 2024. The meeting details and documentation will be accessible on the company’s website in the ‘Investors’ section, as well as on the SEC’s website. Interested shareholders are invited to register for the event following the instructions provided in the meeting notice.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.